Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue: +16.7%
EPS: +747.9%
Free cash flow: −4.76%
Total debt: −2.66%

Quarter to September 2026, against a year earlier

156.28 0.38 −0.24%

Follow ALNY

Alert me

Market cap: $21.0B
P/E: 7.9×
Fwd P/E: 13.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) revenue by segment, product and region

	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021
ONPATTRO	‡	‡	‡	‡	‡	‡	‡	‡
GIVLAARI	‡	‡	‡	‡	‡	‡	‡	‡
Net revenues from collaborations	‡	‡	‡	‡	‡	‡	‡	‡
AMVUTTRA	‡	‡	‡	‡	‡	‡	‡	‡
OXLUMO	‡	‡	‡	‡	‡	‡	‡	‡
Royalty revenue	‡	‡	‡	‡	‡	‡	‡	‡
Net product revenues	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Alnylam Pharmaceuticals, Inc. (ALNY) revenue by segment, product and region

Stockrow Weekly